Senior Management
Professor Greg Hannon,
Director
Prof Hannon joined the Institute in 2014 as a Senior Group Leader, after spending more than 20 years at Cold Spring Harbor Laboratory in New York. He became Director on 1 February 2018, taking over from Professor Simon Tavaré. Read more.
Karen Woodey,
Director of Operations
Karen Woodey joined as Director of Operations on 1 August 2019. Karen is responsible for all aspects of the operation of the Institute including long-term strategic planning and providing support and infrastructure to the Director.
Executive committee
Prof Sir Steve Jackson,
Associate Director of Enterprise and Partnerships
Prof Sir Steve Jackson is a Senior Group Leader at the CRUK CI and the University of Cambridge Frederick James Quick Professor of Biology. He has founded three biotech companies : KuDOS Pharmaceuticals, Mission Therapeutics, and Adrestia Therapeutics.
Dr Raza Ali,
Associate Director of Clinical Research
Dr Raza Ali joined the Institute as a Group Leader in 2020. His research models how the tumour-immune interaction changes over time in breast cancer.
Dr Maike de la Roche,
Associate Director of Research Culture and Innovation
Dr Maike de la Roche joined the Institute in 2016 as a Sir Henry Dale Fellow and Group Leader. Her work focuses on Hedgehog signalling in the immune system.
Prof Jason Carroll,
Associate Director of Research Culture and Innovation
Prof Jason Carroll is a Senior Group Leader at the Institute and Professor of Molecular Oncology within the University. His research focuses on nuclear receptor transcription.
Prof Florian Markowetz,
Associate Director of Artificial Intelligence
Prof Florian Markowetz is a Senior Group Leader at the Institute and Professor of Computational Oncology within the University. His research focuses on developing technologies for the clinic.
Prof Richard Gilbertson,
Director of the CRUK CC
Prof Richard Gilbertson is a senior Group Leader at the Institute and the Director of the CRUK Major Centre in Cambridge. He also serves as the Joint Delivery Board co-chair and research lead for the Cambridge Cancer Research Hospital.
Scientific Advisory Board
The Institute is guided and supported by an international Scientific Advisory Board.
The Board visits the Institute annually and is shared with the CRUK Cambridge Centre, to ensure the two are working in alignment.
Prof Douglas Fearon,
Cold Spring Harbor Laboratory
The Fearon laboratory studies the interaction between cancer and the immune system. Read more.
Prof Elaine Fuchs,
The Rockefeller University
Fuchs is renowned for her research in skin biology, its stem cells and associated genetic disorders, particularly cancers. Read more.
Prof Daphne Haas-Kogan,
Dana-Farber Cancer Institute
The Haas-Kogan laboratory characterises aberrant signaling pathways in brain tumors and pediatric cancers
Prof Peter Jones,
Van Andel Research Institute
Jones’ laboratory discovered the effects of 5-azacytidine on cytosine methylation and first established the link between DNA methylation, gene expression and differentiation. Read more.
Dr John Marioni,
Genentech Research and Early Development
Marioni’s research uses computational models and statistical approaches to integrate and analyse omics cell data. Read more.
Ann Russell,
Patient Advocate
Russell has been a patient advocate since 2010. She is a founding member of the Cancer Patient Advisory Group at Cambridge University Hospital, involved in a wide range of patient fora and has taken part in various cancer trials and studies. Read more.
Prof Karen Vousden,
Francis Crick Institute
Vousden’s research has contributed to our understanding of how the tumour suppressor protein p53 is regulated and functions to control cancer progression. Read more.